Ep. 100: Your Index Got Concentrated — The Income Playbook (OVL, CSHI, Tap Alpha, ABBV vs LLY, KMB)

6 sources on one throughline — the S&P 500 became a concentrated, growth-led bet as the old tailwinds fade, so what does a disciplined income investor do? (1) Our featured piece 'Your Index Fund Isn't as Diversified as You Think' — cap-weight S&P ~36% tech / top-10 >a third vs equal-weight RSP ~20%; the four fading tailwinds; income toolkit as the response. (2) OVL — beats S&P total return via put spreads not covered calls; uncapped upside, but short-vol downside (loses on equity AND puts in a selloff). (3) CSHI — T-bills + modest put-spread overlay, 1-1.5% over bills, the optimized cash sleeve vs SGOV/money market. (4) Tap Alpha T6/TDAX — leveraged (30% via swaps) covered-call income, ~20-24% weekly-paid distributions, mostly ROC. (5) AbbVie vs Eli Lilly — ABBV the better DIVIDEND stock (2.65% yield, Dividend King, Skyrizi/Rinvoq) vs LLY the growth stock (0.57% yield, obesity drugs). (6) Kimberly-Clark — 4.58% Dividend King up 13.7% YTD beating the S&P, 15.2x vs 21.9x median P/E, Kenvue acquisition.